Outlook Therapeutics (OTLK) Cash from Investing Activities (2015 - 2019)
Outlook Therapeutics (OTLK) reported Cash from Investing Activities of -$1.0 for Q3 2019, up 100.0% year-over-year from -$0.5 in Q3 2018, and up 100.0% quarter-over-quarter from -$150737.0 in Q2 2019.
Outlook Therapeutics (OTLK) Cash from Investing Activities (2015 - 2019) Analysis & Trends
Outlook Therapeutics (OTLK) has 5 years of Cash from Investing Activities data on file, last reported at -$1.0 in Q3 2019.
- Cash from Investing Activities for Q3 2019 came in at -$1.0, up 100.0% year-over-year; the trailing twelve-month figure through Sep 2020 was -$200874.0 (up 54.07% YoY), and the FY2020 annual result was -$900000.0, down 105.81% from the prior year.
- Cash from Investing Activities advanced to -$1.0 in Q3 2019 per OTLK's latest filing, from -$150737.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $46949.0 in Q1 2016 and troughed at -$3.5 million in Q2 2015.
- A 5-year average of -$632910.3 and a median of -$202226.5 in 2018 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2018 and 2019: Cash from Investing Activities slumped 5165.95% in 2018, then jumped 100.0% in 2019.
- A 5-year view of Cash from Investing Activities shows it stood at -$364242.0 in 2015, then surged by 59.27% to -$148362.0 in 2016, then tumbled by 624.68% to -$1.1 million in 2017, then soared by 78.01% to -$236433.0 in 2018, then soared by 100.0% to -$1.0 in 2019.
- Business Quant data shows OTLK's Cash from Investing Activities at -$1.0 in Q3 2019, -$150737.0 in Q2 2019, and -$50136.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Outlook Therapeutics | 63.14 Mn | 55.40 Mn | -21,888.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -1.00 |
| Sep 30, 2019 | -1.00 |
| Jun 30, 2019 | -150,737.00 |
| Jun 30, 2019 | -150,737.00 |
| Mar 31, 2019 | -50,136.00 |
| Mar 31, 2019 | -50,136.00 |
| Dec 31, 2018 | -236,433.00 |
| Dec 31, 2018 | -236,433.00 |
| Sep 30, 2018 | -1.26 Mn |
| Sep 30, 2018 | -1.26 Mn |
| Jun 30, 2018 | -168,020.00 |
| Jun 30, 2018 | -168,020.00 |
| Mar 31, 2018 | -275,186.00 |
| Mar 31, 2018 | -275,186.00 |
| Dec 31, 2017 | -1.08 Mn |
| Dec 31, 2017 | -1.08 Mn |
| Sep 30, 2017 | -23,980.00 |
| Sep 30, 2017 | -23,980.00 |
| Jun 30, 2017 | -76,229.00 |
| Jun 30, 2017 | -76,229.00 |